Press Releases - 2022-12-10

Date	Title	Company
10-Dec-2022	Takeda présentera des données à l’occasion du 64e congrès annuel de la Société américaine d’hématologie, démontrant son engagement envers les patients atteints de cancers hématologiques et d’autres maladies du sang	Businesswire
10-Dec-2022	Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival at 64th ASH Annual Meeting	Businesswire
10-Dec-2022	MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022	MorphoSys AG
10-Dec-2022	MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting	Businesswire
10-Dec-2022	Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)	Businesswire
10-Dec-2022	Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022	Businesswire
10-Dec-2022	Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting	Businesswire
10-Dec-2022	Takeda apresenta dados no 64º Encontro Anual da Sociedade Americana de Hematologia (ASH), demonstrando compromisso com pacientes com cânceres hematológicos e outras doenças sanguíneas	Businesswire
10-Dec-2022	Takeda presentará datos en el 64.° Congreso Anual de la Sociedad Americana de Hematología (ASH), demostrando su compromiso con los pacientes con cánceres hematológicos y demás enfermedades de la sangre	Businesswire
10-Dec-2022	Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition	Businesswire
10-Dec-2022	Herbolea Biotech and Iberfar Announce Strategic Partnership and Commercial Relationship	Newswire
10-Dec-2022	INVESTOR DEADLINE: NeoGenomics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – NEO	Businesswire
10-Dec-2022	Dental Adhesives Market is expected to enjoy a valuation of US$ 2.31 Bn by the end of the year 2022 \| FMI	MARKITWIRED
10-Dec-2022	Antiepileptic Drugs Market to reach a valuation of ~US$ 26.2 Bn by the year 2032 \| FMI	MARKITWIRED
10-Dec-2022	Monoclonal Antibodies Market is expected to exhibit a CAGR of 12% from 2022 to 2032 \| FMI	MARKITWIRED
10-Dec-2022	Mobile Clinics Market anticipated to achieve a worth of US$ 8.1 billion by the end of 2032 \| FMI	MARKITWIRED
10-Dec-2022	Takeda präsentiert Daten auf der 64. Jahrestagung der American Society of Hematology (ASH) und zeigt Engagement für Patienten mit Blutkrebs und anderen Bluterkrankungen	Businesswire
10-Dec-2022	NEOGENOMICS INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit on Behalf of NEO Investors	Businesswire